BackHologic Overview

Hologic EBIT

Latest ebit for HOLX: $720M, below the Healthcare sector average of $22B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$257.30M
11.97% YoY

As of Dec 31, 2025

Annual EBIT (TTM)

$724.10M
18.88% YoY

Trailing 12 months ending Dec 31, 2025

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Hologic (HOLX) FAQ

The latest EBIT for HOLX is $720M as of December 2025. That compares with $890M in the prior-year period — down 18.9% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Hologic's historical trend and sector peers before judging valuation or financial health.

Over the past year, HOLX's EBIT moved from $890M to $720M — a 18.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Hologic's operating scale or balance-sheet position.

Against Healthcare companies, HOLX currently prints $720M for EBIT, while the sector average sits near $22B. That is roughly 96.8% below the sector mean. Large gaps often invite a closer look at Hologic's growth, margins, and balance sheet.

A EBIT figure of $720M for HOLX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting HOLX's EBIT ($720M), review year-over-year change from $890M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.